The Relationship Between the Blood-Brain-Barrier and the Central Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors

References

• Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14:88–98. doi:10.1038/nrendo.2017.151
   PubMed Web of Science ®Google Scholar
• Bluher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15:288–298. doi:10.1038/s41574-019-0176-8
   PubMed Web of Science ®Google Scholar
• Filippo CD, Cuzzocrea S, Rossi F, Marfella R, D’Amico M. Oxidative stress as the leading cause of acute myocardial infarction in diabetics. Cardiovasc Drug Rev. 2006;24:77–87. doi:10.1111/j.1527-3466.2006.00077.x
   PubMed Web of Science ®Google Scholar
• Alloubani A, Saleh A, Abdelhafiz I. Hypertension and diabetes mellitus as a predictive risk factors for stroke. Diabetes Metab Syndr. 2018;12:577–584. doi:10.1016/j.dsx.2018.03.009
   Web of Science ®Google Scholar
• Gong M, Wen S, Nguyen T, et al. Converging relationships of obesity and hyperuricemia with special reference to metabolic disorders and plausible therapeutic implications. Diabetes Metab Syndr Obes. 2020;13:943–962. doi:10.2147/DMSO.S232377
   PubMed Web of Science ®Google Scholar
• Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8:728–742. doi:10.1038/nrendo.2012.140
   PubMed Web of Science ®Google Scholar
• Kanoski SE, Fortin SM, Arnold M, Grill HJ, Hayes MR. Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology. 2011;152(8):3103–3112. doi:10.1210/en.2011-0174
   PubMed Web of Science ®Google Scholar
• Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res. 2015;12:78–89. doi:10.1177/1479164114561992
   PubMed Web of Science ®Google Scholar
• Brown RE, Gupta N, Aronson R. Effect of dapagliflozin on glycemic control, weight, and blood pressure in patients with type 2 diabetes attending a specialist endocrinology practice in canada: a retrospective cohort analysis. Diabetes Technol Ther. 2017;19:685–691. doi:10.1089/dia.2017.0134
   PubMed Web of Science ®Google Scholar
• Cai X, Yang W, Gao X, et al. The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: a meta-analysis. Obesity. 2018;26:70–80. doi:10.1002/oby.22066
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Frias J, Pall D, et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab. 2018;20:520–529. doi:10.1111/dom.13103
   PubMed Web of Science ®Google Scholar
• Khat DZ, Husain M. Molecular mechanisms underlying the cardiovascular benefits of SGLT2i and GLP-1RA. Curr Diab Rep. 2018;18:45. doi:10.1007/s11892-018-1011-7
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–1844. doi:10.1056/NEJMoa1607141
   PubMed Web of Science ®Google Scholar
• Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31–39. doi:10.1016/S0140-6736(18)32590-X
   PubMed Web of Science ®Google Scholar
• Wen S, Nguyen T, Gong M, et al. An overview of similarities and differences in metabolic actions and effects of central nervous system between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium glucose co-transporter-2 inhibitors (SGLT-2is). Diabetes Metab Syndr Obes. 2021;14:2955–2972. doi:10.2147/DMSO.S312527
   Web of Science ®Google Scholar
• Zhou L, Sutton GM, Rochford JJ, et al. Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways. Cell Metab. 2007;6:398–405. doi:10.1016/j.cmet.2007.10.008
   PubMed Web of Science ®Google Scholar
• Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37:13–25. doi:10.1016/j.nbd.2009.07.030
   PubMed Web of Science ®Google Scholar
• Acharya NK, Levin EC, Clifford PM, et al. Diabetes and hypercholesterolemia increase blood-brain barrier permeability and brain amyloid deposition: beneficial effects of the LpPLA2 inhibitor darapladib. J Alzheimers Dis. 2013;35:179–198. doi:10.3233/JAD-122254
   Web of Science ®Google Scholar
• Starr JM, Wardlaw J, Ferguson K, MacLullich A, Deary IJ, Marshall I. Increased blood–brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. J Neurol Neurosurg Psychiatry. 2003;74:70–76. doi:10.1136/jnnp.74.1.70
   PubMed Web of Science ®Google Scholar
• Mauro C, De Rosa V, Marelli-Berg F, Solito E. Metabolic syndrome and the immunological affair with the blood-brain barrier. Front Immunol. 2014;5:677. doi:10.3389/fimmu.2014.00677
   Web of Science ®Google Scholar
• Miller AA, Spencer SJ. Obesity and neuroinflammation: a pathway to cognitive impairment. Brain Behav Immun. 2014;42:10–21. doi:10.1016/j.bbi.2014.04.001
   PubMed Web of Science ®Google Scholar
• Pan Y, Nicolazzo JA. Impact of aging, Alzheimer’s disease and Parkinson’s disease on the blood-brain barrier transport of therapeutics. Adv Drug Deliv Rev. 2018;135:62–74. doi:10.1016/j.addr.2018.04.009
   PubMed Web of Science ®Google Scholar
• Pun PB, Lu J, Moochhala S. Involvement of ROS in BBB dysfunction. Free Radic Res. 2009;43:348–364. doi:10.1080/10715760902751902
   PubMed Web of Science ®Google Scholar
• Terami N, Ogawa D, Tachibana H, et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One. 2014;9:e100777. doi:10.1371/journal.pone.0100777
   PubMed Web of Science ®Google Scholar
• Abbott NJ. Dynamics of CNS barriers: evolution, differentiation, and modulation. Cell Mol Neurobiol. 2005;25:5–23. doi:10.1007/s10571-004-1374-y
   PubMed Web of Science ®Google Scholar
• Alexander JJ. Blood-brain barrier (BBB) and the complement landscape. Mol Immunol. 2018;102:26–31. doi:10.1016/j.molimm.2018.06.267
   PubMed Web of Science ®Google Scholar
• Norsted E, Gomuc B, Meister B. Protein components of the blood-brain barrier (BBB) in the mediobasal hypothalamus. J Chem Neuroanat. 2008;36:107–121. doi:10.1016/j.jchemneu.2008.06.002
   PubMed Web of Science ®Google Scholar
• Bagchi S, Chhibber T, Lahooti B, et al. In-vitro blood-brain barrier models for drug screening and permeation studies: an overview. Drug Des Devel Ther. 2019;13:3591–3605. doi:10.2147/DDDT.S218708
   PubMed Web of Science ®Google Scholar
• Gawdi R, Emmady PD, Jindal C. Physiology, blood brain barrier. J Thorac Dis. 2021;13(10):5617–5626. doi:10.21037/jtd-21-1018
   Web of Science ®Google Scholar
• Jensen CB, Pyke C, Rasch MG, et al. Characterization of the glucagon like peptide-1 receptor in male mouse brain using a novel antibody and in situ hybridization. Endocrinology. 2018;159(2):665–675. doi:10.1210/en.2017-00812
   Web of Science ®Google Scholar
• Farr OM, Sofopoulos M, Tsoukas MA, et al. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial. Diabetologia. 2016;59:954–965. doi:10.1007/s00125-016-3874-y
   PubMed Web of Science ®Google Scholar
• Holscher C. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer’s and Parkinson’s disease models. Neuropharmacology. 2018;136:251–259. doi:10.1016/j.neuropharm.2018.01.040
   PubMed Web of Science ®Google Scholar
• Lv M, Xue G, Cheng H, et al. The GLP-1/GIP dual-receptor agonist DA5-CH inhibits the NF-kappaB inflammatory pathway in the MPTP mouse model of Parkinson’s disease more effectively than the GLP-1 single-receptor agonist NLY01. Brain Behav. 2021;11:e2231. doi:10.1002/brb3.2231
   PubMed Web of Science ®Google Scholar
• McGovern SF, Hunter K, Holscher C. Effects of the glucagon-like polypeptide-1 analogue (Val8)GLP-1 on learning, progenitor cell proliferation and neurogenesis in the C57B/16 mouse brain. Brain Res. 2012;1473:204–213. doi:10.1016/j.brainres.2012.07.029
   PubMed Web of Science ®Google Scholar
• Bailey J, Barrett A, Coucha M, Abdelsaid MA. Abstract P729: glp-1 receptor nitration contributes to brain pericytes dysfunction in diabetes. Stroke. 2021;52:AP729–AP729. doi:10.1161/str.52.suppl_1.P729
   Web of Science ®Google Scholar
• Fortin SM, Lipsky RK, Lhamo R, et al. GABA neurons in the nucleus tractus solitarius express GLP-1 receptors and mediate anorectic effects of liraglutide in rats. Sci Transl Med. 2020;12. doi:10.1126/scitranslmed.aay8071
   Web of Science ®Google Scholar
• Vanlandewijck M, He L, Mae MA, et al. A molecular atlas of cell types and zonation in the brain vasculature. Nature. 2018;554:475–480. doi:10.1038/nature25739
   PubMed Web of Science ®Google Scholar
• Bhavsar S, Mudaliar S, Cherrington A. Evolution of Exenatide as a Diabetes Therapeutic. Curr Diabetes Rev. 2013;9:161–193. doi:10.2174/1573399811309020007
   PubMedGoogle Scholar
• Werner U, Haschke G, Herling AW, Kramer W. Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul Pept. 2010;164:58–64. doi:10.1016/j.regpep.2010.05.008
   PubMed Web of Science ®Google Scholar
• Tang C, Li Q, Deng X, et al. Discovery of lixisenatide analogues as long-acting hypoglycemic agents using novel peptide half-life extension technology based on mycophenolic acid. RSC Adv. 2020;10:12089–12104. doi:10.1039/D0RA01002B
   Web of Science ®Google Scholar
• Zhang YL, Zhou C, Li XF, et al. Beinaglutide showed significant weight-loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real-world setting: a 3-month, multicentre, observational, retrospective, open-label study. Obes Sci Pract. 2019;5:366–375. doi:10.1002/osp4.342
   PubMed Web of Science ®Google Scholar
• Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374:39–47. doi:10.1016/S0140-6736(09)60659-0
   PubMed Web of Science ®Google Scholar
• Geiser JS, Heathman MA, Cui X, et al. Clinical pharmacokinetics of dulaglutide in patients with type 2 diabetes: analyses of data from clinical trials. Clin Pharmacokinet. 2016;55:625–634. doi:10.1007/s40262-015-0338-3
   PubMed Web of Science ®Google Scholar
• Kalra S, Sahay R. A review on semaglutide: an oral glucagon-like peptide 1 receptor agonist in management of type 2 diabetes mellitus. Diabetes Ther. 2020;11:1965–1982. doi:10.1007/s13300-020-00894-y
   PubMed Web of Science ®Google Scholar
• Jacobsen LV, Flint A, Olsen AK, Ingwersen SH. Liraglutide in type 2 diabetes mellitus: clinical pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2016;55:657–672. doi:10.1007/s40262-015-0343-6
   PubMed Web of Science ®Google Scholar
• Kastin AJ, Akerstrom V, Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci. 2002;18:7–14. doi:10.1385/JMN:18:1-2:07
   PubMed Web of Science ®Google Scholar
• Zhou L, Williams T, Lachey JL, et al. Serotonergic pathways converge upon central melanocortin systems to regulate energy balance. Peptides. 2005;26(10):1728–1732. doi:10.1016/j.peptides.2004.12.028
   PubMed Web of Science ®Google Scholar
• Zhou L, Yueh CY, Lam DD, et al. Glucokinase inhibitor glucosamine stimulates feeding and activates hypothalamic neuropeptide Y and orexin neurons. Behav Brain Res. 2011;222:274–278. doi:10.1016/j.bbr.2011.03.043
   Web of Science ®Google Scholar
• Heisler LK, Jobst EE, Sutton GM, et al. Serotonin reciprocally regulates melanocortin neurons to modulate food intake. Neuron. 2006;51:239–249. doi:10.1016/j.neuron.2006.06.004
   PubMed Web of Science ®Google Scholar
• Brierley DI, Holt MK, Singh A, et al. Central and peripheral GLP-1 systems independently suppress eating. Nature Metabol. 2021;3:258–273. doi:10.1038/s42255-021-00344-4
   Google Scholar
• Plamboeck A, Veedfald S, Deacon CF, et al. The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. Am J Physiol Gastrointest Liver Physiol. 2013;304:G1117–G1127. doi:10.1152/ajpgi.00035.2013
   PubMed Web of Science ®Google Scholar
• Fu Z, Gong L, Liu J, et al. Brain endothelial cells regulate glucagon-like peptide 1 entry into the brain via a receptor-mediated process. Front Physiol. 2020;11:555. doi:10.3389/fphys.2020.00555
   Web of Science ®Google Scholar
• Labouesse MA, Stadlbauer U, Weber E, et al. Vagal afferents mediate early satiation and prevent flavour avoidance learning in response to intraperitoneally infused exendin-4. J Neuroendocrinol. 2012;24(12):1505–1516. doi:10.1111/j.1365-2826.2012.02364.x
   Web of Science ®Google Scholar
• Secher A, Jelsing J, Baquero AF, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124:4473–4488. doi:10.1172/JCI75276
   PubMed Web of Science ®Google Scholar
• Salinas CBG, Lu TT, Gabery S, et al. Integrated brain atlas for unbiased mapping of nervous system effects following liraglutide treatment. Sci Rep. 2018;8:10310. doi:10.1038/s41598-018-28496-6
   Web of Science ®Google Scholar
• Larsen PJ, Tang-Christensen M, Jessop DS. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology. 1997;138:4445–4455. doi:10.1210/endo.138.10.5270
   PubMed Web of Science ®Google Scholar
• McLean BA, Wong CK, Campbell JE, et al. Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation. Endocr Rev. 2021;42(2):101–132. doi:10.1210/endrev/bnaa032
   Web of Science ®Google Scholar
• Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from Guinea pig pancreas. J Biol Chem. 1992;267:7402–7405. doi:10.1016/S0021-9258(18)42531-8
   PubMed Web of Science ®Google Scholar
• Bomfim TR, Forny-Germano L, Sathler LB, et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease- associated Abeta oligomers. J Clin Invest. 2012;122:1339–1353. doi:10.1172/JCI57256
   PubMed Web of Science ®Google Scholar
• Kastin A, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes. 2003;27(3):313–318. doi:10.1038/sj.ijo.0802206
   PubMed Web of Science ®Google Scholar
• Harkavyi A, Abuirmeileh A, Lever R, et al. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson’s disease. J Neuroinflammation. 2008;5:19. doi:10.1186/1742-2094-5-19
   PubMed Web of Science ®Google Scholar
• Mishra SH, Bhavaraju S, Schmidt DR, Carrick KL. Facilitated structure verification of the biopharmaceutical peptide exenatide by 2D heteronuclear NMR maps. J Pharm Biomed Anal. 2021;203:114136. doi:10.1016/j.jpba.2021.114136
   Web of Science ®Google Scholar
• Athauda D, Maclagan K, Skene SS, et al. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:1664–1675. doi:10.1016/S0140-6736(17)31585-4
   PubMed Web of Science ®Google Scholar
• Aviles-Olmos I, Dickson J, Kefalopoulou Z, et al. Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson’s disease. J Parkinsons Dis. 2014;4:337–344. doi:10.3233/JPD-140364
   PubMedGoogle Scholar
• Aviles-Olmos I, Dickson J, Kefalopoulou Z, et al. Exenatide and the treatment of patients with Parkinson’s disease. J Clin Invest. 2013;123:2730–2736. doi:10.1172/JCI68295
   PubMed Web of Science ®Google Scholar
• Salameh TS, Rhea EM, Talbot K, Banks WA. Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer’s and Parkinson’s disease therapeutics. Biochem Pharmacol. 2020;180:114187. doi:10.1016/j.bcp.2020.114187
   PubMed Web of Science ®Google Scholar
• McClean PL, Holscher C. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer’s disease. Neuropharmacology. 2014;86:241–258. doi:10.1016/j.neuropharm.2014.07.015
   PubMed Web of Science ®Google Scholar
• Hunter K, Holscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 2012;13:33. doi:10.1186/1471-2202-13-33
   PubMed Web of Science ®Google Scholar
• McClean PL, Holscher C. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer’s disease. Neuropharmacology. 2014;76(Pt A):57–67. doi:10.1016/j.neuropharm.2013.08.005
   PubMed Web of Science ®Google Scholar
• McClean PL, Parthsarathy V, Faivre E, Holscher C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer’s disease. J Neurosci. 2011;31:6587–6594. doi:10.1523/JNEUROSCI.0529-11.2011
   PubMed Web of Science ®Google Scholar
• Liu W, Jalewa J, Sharma M, et al. Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. Neuroscience. 2015;303:42–50. doi:10.1016/j.neuroscience.2015.06.054
   PubMed Web of Science ®Google Scholar
• Glaesner W, Vick AM, Millican R, et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev. 2010;26:287–296. doi:10.1002/dmrr.1080
   PubMed Web of Science ®Google Scholar
• Gabery S, Salinas CG, Paulsen SJ, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5. doi:10.1172/jci.insight.133429
   PubMed Web of Science ®Google Scholar
• Chen J, Williams S, Ho S, et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther. 2010;1:57–92. doi:10.1007/s13300-010-0006-4
   PubMedGoogle Scholar
• Yu AS, Hirayama BA, Timbol G, et al. Functional expression of SGLTs in rat brain. Am J Physiol Cell Physiol. 2010;299:C1277–C1284. doi:10.1152/ajpcell.00296.2010
   PubMed Web of Science ®Google Scholar
• Yu AS, Hirayama BA, Timbol G, et al. Regional distribution of SGLT activity in rat brain in vivo. Am J Physiol Cell Physiol. 2013;304:C240–C247. doi:10.1152/ajpcell.00317.2012
   PubMed Web of Science ®Google Scholar
• Shah K, Desilva S, Abbruscato T. The role of glucose transporters in brain disease: diabetes and Alzheimer’s Disease. Int J Mol Sci. 2012;13:12629–12655. doi:10.3390/ijms131012629
   PubMed Web of Science ®Google Scholar
• Chiba Y, Sugiyama Y, Nishi N, et al. Sodium/glucose cotransporter 2 is expressed in choroid plexus epithelial cells and ependymal cells in human and mouse brains. Neuropathology. 2020;40(5):482–491. doi:10.1111/neup.12665
   Web of Science ®Google Scholar
• Shin SJ, Chung S, Kim SJ, et al. Effect of sodium-glucose co-transporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes. PLoS One. 2016;11:e0165703. doi:10.1371/journal.pone.0165703
   PubMed Web of Science ®Google Scholar
• Puglisi S, Rossini A, Poli R, et al. Effects of SGLT2 inhibitors and GLP-1 receptor agonists on renin-angiotensin-aldosterone system. Front Endocrinol. 2021;12:738848. doi:10.3389/fendo.2021.738848
   PubMed Web of Science ®Google Scholar
• Nguyen T, Wen S, Gong M, et al. Dapagliflozin activates neurons in the central nervous system and regulates cardiovascular activity by inhibiting SGLT-2 in mice. Diabetes Metab Syndr Obes. 2020;13:2781–2799. doi:10.2147/DMSO.S258593
   PubMed Web of Science ®Google Scholar
• Gray MT, Woulfe JM. Striatal blood-brain barrier permeability in Parkinson’s disease. J Cereb Blood Flow Metab. 2015;35:747–750. doi:10.1038/jcbfm.2015.32
   PubMed Web of Science ®Google Scholar
• Bowen Lin NK, Hasegawa Y, Sueta D, et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. 2014;13:1–5.
   Web of Science ®Google Scholar
• El-Sahar AE, Rastanawi AA, El-Yamany MF, Saad MA. Dapagliflozin improves behavioral dysfunction of Huntington’s disease in rats via inhibiting apoptosis-related glycolysis. Life Sci. 2020;257:118076. doi:10.1016/j.lfs.2020.118076
   PubMed Web of Science ®Google Scholar
• Millar P, Pathak N, Parthsarathy V, et al. Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice. J Endocrinol. 2017;234:255–267. doi:10.1530/JOE-17-0263
   PubMed Web of Science ®Google Scholar
• Shaikh S, Rizvi SMD, Shakil S, et al. Forxiga (dapagliflozin): plausible role in the treatment of diabetes-associated neurological disorders. Biotechnol Appl Biochem. 2016;63:145–150. doi:10.1002/bab.1319
   Web of Science ®Google Scholar
• Hayden MR, Grant DG, Aroor AR, DeMarco VG. Empagliflozin ameliorates type 2 diabetes-induced ultrastructural remodeling of the neurovascular unit and neuroglia in the female db/db mouse. Brain Sci. 2019;9(3):57. doi:10.3390/brainsci9030057
   Web of Science ®Google Scholar
• Amin EF, Rifaai RA, Abdel-Latif RG. Empagliflozin attenuates transient cerebral ischemia/reperfusion injury in hyperglycemic rats via repressing oxidative-inflammatory-apoptotic pathway. Fundam Clin Pharmacol. 2020;34:548–558. doi:10.1111/fcp.12548
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384:117–128. doi:10.1056/NEJMoa2030183
   PubMed Web of Science ®Google Scholar
• Pawlos A, Broncel M, Wozniak E, Gorzelak-Pabis P. Neuroprotective effect of SGLT2 inhibitors. Molecules. 2021;26(23):7213. doi:10.3390/molecules26237213
   PubMed Web of Science ®Google Scholar
• Cosentino F, Cannon CP, Cherney DZI, et al. Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial. Circulation. 2020;142:2205–2215. doi:10.1161/CIRCULATIONAHA.120.050255
   PubMed Web of Science ®Google Scholar
• Matharu K, Chana K, Ferro CJ, Jones AM. Polypharmacology of clinical sodium glucose co-transport protein 2 inhibitors and relationship to suspected adverse drug reactions. Pharmacol Res Perspect. 2021;9:e00867. doi:10.1002/prp2.867
   Web of Science ®Google Scholar
• Markham A, Elkinson S. Luseogliflozin: first global approval. Drugs. 2014;74:945–950. doi:10.1007/s40265-014-0230-8
   PubMed Web of Science ®Google Scholar
• Wang S, Fan F. Oral antihyperglycemic therapy with a SGLT2 inhibitor reverses cognitive impairments in elderly diabetics. Hypertension. 2019;74:A051–A051. doi:10.1161/hyp.74.suppl_1.051
   Web of Science ®Google Scholar
• Wang S, Jiao F, Border JJ, et al. Luseogliflozin, a sodium-glucose cotransporter-2 inhibitor, reverses cerebrovascular dysfunction and cognitive impairments in 18-mo-old diabetic animals. Am J Physiol Heart Circ Physiol. 2022;322:H246–H259. doi:10.1152/ajpheart.00438.2021
   Web of Science ®Google Scholar
• Takeda K, Ono H, Ishikawa K, et al. Central administration of sodium-glucose cotransporter-2 inhibitors increases food intake involving adenosine monophosphate-activated protein kinase phosphorylation in the lateral hypothalamus in healthy rats. BMJ Open Diabetes Res. 2021;9(1):e002104. doi:10.1136/bmjdrc-2020-002104
   Web of Science ®Google Scholar
• Lin KJ, Wang TJ, Chen SD, et al. Two birds one stone: the neuroprotective effect of antidiabetic agents on parkinson disease-focus on sodium-glucose cotransporter 2 (SGLT2) inhibitors. Antioxidants. 2021;10:1935. doi:10.3390/antiox10121935
   Web of Science ®Google Scholar
• Yokono M, Takasu T, Hayashizaki Y, et al. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol. 2014;727:66–74. doi:10.1016/j.ejphar.2014.01.040
   PubMed Web of Science ®Google Scholar
• Rizvi SM, Shakil S, Biswas D, et al. Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: advancement in Alzheimer’s disease- diabetes type 2 linkage via an enzoinformatics study. CNS Neurol Disord Drug Targets. 2014;13(3):447–451. doi:10.2174/18715273113126660160
   Web of Science ®Google Scholar
• Naznin F, Sakoda H, Okada T, et al. Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice. Eur J Pharmacol. 2017;794:37–44. doi:10.1016/j.ejphar.2016.11.028
   PubMed Web of Science ®Google Scholar
• Arafa NM, Marie MA, AlAzimi SA. Effect of canagliflozin and metformin on cortical neurotransmitters in a diabetic rat model. Chem Biol Interact. 2016;258:79–88. doi:10.1016/j.cbi.2016.08.016
   PubMed Web of Science ®Google Scholar
• Sha W, Wen S, Chen L, et al. The role of SGLT2 inhibitor on the treatment of diabetic retinopathy. J Diabetes Res. 2020;2020:8867875. doi:10.1155/2020/8867875
   PubMed Web of Science ®Google Scholar
• Hawkins BT, Lundeen TF, Norwood KM, Brooks HL, Egleton RD. Increased blood-brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases. Diabetologia. 2007;50:202–211. doi:10.1007/s00125-006-0485-z
   PubMed Web of Science ®Google Scholar
• Bogush M, Heldt NA, Persidsky Y. Blood brain barrier injury in diabetes: unrecognized effects on brain and cognition. J Neuroimmune Pharmacol. 2017;12:593–601. doi:10.1007/s11481-017-9752-7
   Web of Science ®Google Scholar
• Banks WA. The blood-brain barrier interface in diabetes mellitus: dysfunctions, mechanisms and approaches to treatment. Curr Pharm Des. 2020;26:1438–1447. doi:10.2174/1381612826666200325110014
   Web of Science ®Google Scholar
• Serlin Y, Levy J, Shalev H. Vascular pathology and blood-brain barrier disruption in cognitive and psychiatric complications of type 2 diabetes mellitus. Cardiovasc Psychiatry Neurol. 2011;2011:609202. doi:10.1155/2011/609202
   PubMedGoogle Scholar
• Thackeray JT, Hupe HC, Wang Y, et al. Myocardial Inflammation Predicts Remodeling and Neuroinflammation After Myocardial Infarction. J Am Coll Cardiol. 2018;71:263–275. doi:10.1016/j.jacc.2017.11.024
   PubMed Web of Science ®Google Scholar
• Volpe CMO, Villar-Delfino PH, Dos Anjos PMF, Nogueira-Machado JA. Cellular death, reactive oxygen species (ROS) and diabetic complications. Cell Death Dis. 2018;9:119. doi:10.1038/s41419-017-0135-z
   PubMed Web of Science ®Google Scholar
• Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes. 2004;53:2079–2086. doi:10.2337/diabetes.53.8.2079
   PubMed Web of Science ®Google Scholar
• Shu CJ, Benoist C, Mathis D. The immune system’s involvement in obesity-driven type 2 diabetes. Semin Immunol. 2012;24:436–442. doi:10.1016/j.smim.2012.12.001
   PubMed Web of Science ®Google Scholar
• Ouyang S, Hsuchou H, Kastin AJ, et al. Diet-induced obesity suppresses expression of many proteins at the blood-brain barrier. J Cereb Blood Flow Metab. 2014;34:43–51. doi:10.1038/jcbfm.2013.166
   PubMed Web of Science ®Google Scholar
• Davidson TL, Monnot A, Neal AU, et al. The effects of a high-energy diet on hippocampal-dependent discrimination performance and blood-brain barrier integrity differ for diet-induced obese and diet-resistant rats. Physiol Behav. 2012;107:26–33. doi:10.1016/j.physbeh.2012.05.015
   PubMed Web of Science ®Google Scholar
• Braniste V, Al-Asmakh M, Kowal C, et al. The gut microbiota influences blood-brain barrier permeability in mice. Sci Transl Med. 2014;6:263ra158–263ra158. doi:10.1126/scitranslmed.3009759
   PubMed Web of Science ®Google Scholar
• Frohlich EE, Farzi A, Mayerhofer R, et al. Cognitive impairment by antibiotic-induced gut dysbiosis: analysis of gut microbiota-brain communication. Brain Behav Immun. 2016;56:140–155. doi:10.1016/j.bbi.2016.02.020
   PubMed Web of Science ®Google Scholar
• O’Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep. 2006;7:688–693. doi:10.1038/sj.embor.7400731
   PubMed Web of Science ®Google Scholar
• Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Human gut microbes associated with obesity. Nature. 2006;444:1022–1023. doi:10.1038/4441022a
   PubMed Web of Science ®Google Scholar
• Tilg H, Moschen AR. Microbiota and diabetes: an evolving relationship. Gut. 2014;63:1513–1521. doi:10.1136/gutjnl-2014-306928
   PubMed Web of Science ®Google Scholar
• Vieira AT, Galvao I, Macia LM, et al. Dietary fiber and the short-chain fatty acid acetate promote resolution of neutrophilic inflammation in a model of gout in mice. J Leukoc Biol. 2017;101:275–284. doi:10.1189/jlb.3A1015-453RRR
   PubMed Web of Science ®Google Scholar
• Liu X, Cao S, Zhang X. Modulation of gut microbiota-brain axis by probiotics, prebiotics, and diet. J Agric Food Chem. 2015;63:7885–7895. doi:10.1021/acs.jafc.5b02404
   PubMed Web of Science ®Google Scholar
• Toccaceli G, Barbagallo G, Peschillo S. Low-intensity focused ultrasound for the treatment of brain diseases: safety and feasibility. Theranostics. 2019;9:537–539. doi:10.7150/thno.31765
   PubMed Web of Science ®Google Scholar
• Xie J, Shen Z, Anraku Y, Kataoka K, Chen X. Nanomaterial-based blood-brain-barrier (BBB) crossing strategies. Biomaterials. 2019;224:119491. doi:10.1016/j.biomaterials.2019.119491
   PubMed Web of Science ®Google Scholar